Combination Chemotherapy for Hormone-Refractory Prostate Carcinoma: Progress and Pitfalls

Although there has been progress in the development of chemotherapy combinations with enhanced activity in patients with hormone-refractory prostate carcinoma, the innate lack of selectivity to tumor cells with those combinations has resulted in diminishing returns and has approached the limits of acceptable toxicity. However, progress is being made, and several promising new therapies offer the dual hopes of maximizing efficacy with minimal toxicity to normal tissues.